巻号一覧
8 巻 (1977)
- 4 号 p. 421-
- 3 号 p. 265-
- 2 号 p. 137-
- 1 号 p. 1-
8 巻, 4 号
選択された号の論文の12件中1～12を表示しています
- |<
- <
- 1
- >
- >|
-
高木 敬次郎1977 年 8 巻 4 号 p. 421-423
発行日: 1977/12/30
公開日: 2010/06/28
ジャーナル フリーPDF形式でダウンロード (547K) -
妊婦における鉄剤の排便抑制作用の検討今村 弘, 宮崎 好信, 大塚 明, 森川 信博, 江川 淳治, 森永 高弘, 栗谷 典量, 大谷 靖世, 米虫 節夫, 山内 士具1977 年 8 巻 4 号 p. 425-432
発行日: 1977/12/30
公開日: 2010/06/28
ジャーナル フリーThe inhibitory effect of ferrous fumarate (FeF) on bowel movements was studied using cross-over technique under the double blind method in pregnancies of twelve to thirty-two weeks of gestation. The subjects had more than 5 defecation days in a 2-week medication-free observation period.
Daily oral doses of four tablets of either FeF (300 mg) or placebo were given for two weeks, and then crossed over for another two weeks.
The number of subjects was 116 in total, of which 70 cases were in the preceding placebo group and 46 cases were in the preceding FeF group. Drop out cases were significantly more in the preceding FeF group because the patients easily noticed the discoloration of feces when the medication was crossed from FeF to placebo.
In respect of the bowel movements the number of days with defecation and frequency of defecation during each 14-day period were determined. During the preceding control period no significant difference was observed by the groupcomparison analysis between the two groups.
A sign test revealed that the number of days and frequency decreased significantly in the FeF administration period in both groups.
The cross-over analysis between FeF and placebo revealed a significant decrement in the number of days and frequency by FeF administration, but no other significant effect was found in the analysis.抄録全体を表示PDF形式でダウンロード (1060K) -
妊婦貧血における鉄剤 (FeD錠) の臨床効果今村 弘, 宮崎 好信, 大塚 明, 森川 信博, 江川 淳治, 森永 高弘, 栗谷 典量, 大谷 靖世, 米虫 節夫, 山内 士具1977 年 8 巻 4 号 p. 433-444
発行日: 1977/12/30
公開日: 2010/06/28
ジャーナル フリーThe therapeutic effects of FeD tablet containing 75 mg of ferrous fumarate (FeF) and 50mg of dioctyl sodium sulfosuccinate (DSS) on anemia in pregnant women and constipation which develops as a complication due to pregnancy itself and as the side effect of FeF treatment for anemia in pregnancy was studied.
Hemoglobin, red blood cell, number of days with defecation and frequency of defecation were used as the parameters of this study.
114 pregnant women, twelve to thirty-two weeks of gestation, who had more than 5 defecation days in a 2-week preceding control period (0-period) were orally medicated with FeF (Pre-FeF) at daily doses of 300 mg (4 tablets) for two weeks (1st period). Thereafter the cross-over study was conducted. After the administration of Pre-FeF for 2 weeks, the subjects were devided into two groups of FeD (G1, 57 cases) and FeF (G2, 57 cases), and daily doses of four tablets of either Fed or FeF were given for two weeks (2 nd period). Then the drugs were crossed over for another two weeks (3 rd period). The cross-over technique under the double blind method was used.
Balanced judgement was made in each case on to which drug had greater clinical effects considering the all parameters observed during the four periods of this study. This judgement was solely made by Dr. Imamura, one of the members of this investigation team. In this balanced judgement, FeD was found to be significantly superior to FeF in 63 out of 114 cases (53.3%) and inferior in 14 cases (12.3%).
In both groups, both hemoglobin and red cells increased significantly during the 3 rd period and at the end of total period, but did not show any differences between FeD and FeF in the cross-over analysis.
As to bowel movements, days and frequency of defecation were significantly increased by FeD and decreased by FeF.抄録全体を表示PDF形式でダウンロード (1571K) -
抗不安効果との関連性田中 正敏, 磯崎 宏, 稲永 和豊1977 年 8 巻 4 号 p. 445-451
発行日: 1977/12/30
公開日: 2010/06/28
ジャーナル フリーEffects of prazepam and diazepam on the latencies of the PPR were studied in 8 male, healthy volunteers. Drugs were administered orally in a cross-over design with a double-blind method and subsequently the PPR was recorded repeatedly. The self-assessments after dosing were checked. Diazepam 5 mg prolonged the P1 latency significantly as compared with placebo 2 hours after dosing. Prazepam 10 mg and 20mg prolonged the P1 latency depending on the doses. The degree of the prolongation of P1 latency after diazepam 5 mg administration was stronger than that after prazepam 20mg. Prazepam prolonged the P2 latency in a dose-depend-ent manner and showed the maximal prolongation 2 hours after medication. Compared with placebo, prazepam 20mg and diazepam 5mg prolonged the P2 latency significantly 2 and 3 hours after medication, while the prolongation of P2 latency after the former administration was more marked than that after the latter. From these results, it was suggested that prazepam had an anxiolytic action and its most effective time might be 2 or 3 hours after medication and the equipotent dose of prazepam to diazepam 5mg might be 15-20mg.抄録全体を表示PDF形式でダウンロード (1135K) -
クル病を発症したてんかん患児7例の病態三牧 孝至, 隅 清臣, 杉田 隆博, 清水 寛, 岡田 伸太郎, 清野 佳紀, 下辻 常介, 藪内 百治1977 年 8 巻 4 号 p. 453-463
発行日: 1977/12/30
公開日: 2010/06/28
ジャーナル フリーSeven children who were suffered from rickets during administration of anti-convulsants were studied. In this study, the effects of anticonvulsants on liver and bone metabolism were discussed. The serum levels of 25-hydroxycholecalciferol were measured in all cases, and in three cases, serum parathyroid hormone le-vels were also measured.
In six of seven patients, the serum levels of 25-hydroxycholecalciferol were subnormal or markedly low. And the serum levels of parathyroid hormone were markedly elevated in two of three patients.
In all seven cases, serum alkaline phosphatase levels were markedly elevated. And in three of these patients, serum γ-glutamyl transpeptidase levels were also elevated without the increase of serum GPT or GOT.
Though serum calcium levels were not always decreased, serum inorganic phosphorus levels were markedly low in all seven cases.
All these patients were administered phenobarbital and acetazolamide. In six of them, metabolic acidosis was observed, and after elimination of acetazolamide, metabolic acidosis was corrected in five patients. And in two of them, the improvement of rachitic change occurred only after elimination of acetazolamide. These findings suggest the important role of acetazolamide in the development of rickets.
Since the anticonvulsants such as phenobarbital and diphenylhydantoin accelerate the inactivation of vitamin D activity, the administration of these anticonvulsants seems to increase the requirement of vitamin D.抄録全体を表示PDF形式でダウンロード (5209K) -
寺沢 富士夫, 池田 正男, 栗原 博, 鈴木 孝臣1977 年 8 巻 4 号 p. 465-469
発行日: 1977/12/30
公開日: 2010/06/28
ジャーナル フリーThe hypotensive effect of Pyratrione [3- (3-hydroxy-hydrocinamoyl) -b-me-thyl-2H-pyran-2, 4 (3H) -dione] has been demonstrated in spontaneously hyper-tensive rabbits. This study was undertaken to see whether or not this agent could significantly lower the blood pressure of chronic Goldblatt type hypertension of rabbits. The result showed that successive 3 days adminitstration of this agent effectively lowered the blood pressure of these hypertensive rabbits, when com-pared with the blood pressure in pre-and post-administration phases of these animals as well as with the blood pressure of the control rabbits.抄録全体を表示PDF形式でダウンロード (688K) -
Propranololとの比較寺沢 富士夫, 池田 正男, 鈴木 孝臣, リー ホン・ユーイング, 関 増爾1977 年 8 巻 4 号 p. 471-484
発行日: 1977/12/30
公開日: 2010/06/28
ジャーナル フリーThe hemodynamic effects of intravenously administered Ko 1366 were studied in old normotensive and hypertensive subjects at resting supine position and compared with the effects of propranolol.
Rate of change in cardiac index (CI) and stroke volume index (SVI) was slightly less by Kö1366 in normotensive and hypertensive subjects than that by propranolol.
In the subjects with normal CI among normotensive subjects, the decrease in CI by K6 1366 was lower than that by propranolol. Moreover, in the subjects with lower CI, CI and SVI increased by Kö1366.
In the subjects with higher CI among hypertensive subjects, the rate of change in CI and SVI showed a tendency to decrease slightly by Ko 1366 than that by propranolol. However, in the subjects with normal CI, the rate of change in CI and SVI by Kö1366 was not significantly different when compared with that by propranolol. In the subjects without electrocardiographic changes of left ventricular hypertrophy among hypertensive subjects, SVI showed a tendency to increase by Kö 1366, while it decreased by propranolol. In the subjects with electrocardiographic changes, both CI and SVI increased by Kö1366, whereas they decreased by propranolol.
These results suggested that the intrinsic sympathomimetic activity of Kö1366 manifested when cardiac function of old subjects was depressed. This could be the advantage of Kö1366 over propranolol in the treatment of old subjects with cardiac disease.抄録全体を表示PDF形式でダウンロード (1966K) -
1-2回経口投与実験関 隆1977 年 8 巻 4 号 p. 485-494
発行日: 1977/12/30
公開日: 2010/06/28
ジャーナル フリーTen healthy male adult volunteers received each of the six oral dose levels of sodium salt of AA-149, a new spasmolytic-cholenetic, to determine their tolerance, absorption and excretion.The dose levels ranged from 10 to 100mg as AA-149. The subjects were given the drug in two doses with an interval of 23 hours except for two. Subjective and objective symptoms were recorded, and blood analysis, blood chemistry tests, urinalysis, physiological function tests as well as determination of serum drug levels and urinary excretion were performed.
The subjects receiving 20mg or more of AA-149 represented a suppressed bowel sound, which was the most characteristic finding in the present study, indicating the spasmolytic action of the drug. The intensity of the suppression, however, was not shown to be clearly related to the dose levels. As subjective symptoms, two subjects of lower dose levels (10 and 20mg) claimed some transient complaints of a slight degree (dull pain in the stomach, epigastric discomfort and feeling of dry mouth).
No abnormal objective findings and laboratory test values were recognized, but serum bilirubin transiently and doseindependently elevated in all the cases within the physiologically normal range.
Serum AA-149 levels elevated in proportion to the dose levels and reached maximum of about 1.5 hours following administration.
The half life of the serum level was about one hour. About 50 to 60% of the given AA-149 was recovered as glucuronide in the 24-hour urines. Two urinary metabolites were found in about 10% in total.抄録全体を表示PDF形式でダウンロード (1521K) -
反復経口投与実験関 隆1977 年 8 巻 4 号 p. 495-500
発行日: 1977/12/30
公開日: 2010/06/28
ジャーナル フリーThree healthy male adult volunteers received 9 to 10 oral doses (each being 60, 80, or 120mg) of AA-149 administered three times daily, to determine their tol erance, absorption and exceretion. Subjec tive and objective symptoms were recorded, and blood analysis, blood chemistry tests, urinalysis, physiological function tests as well as detemination of serum drug levels and urinary excretion were performed.
No noteworthy findings attributable to the drug were observed in the record of subjective and objective symptoms and various other test values.
Pharmacokinetic study revealed that the peak of serum levels were higher with higher dosage levels and that the peak tended to appear a little later following administration after lunch and supper, which is thought to be due to the delay in emptying the stomach by the smooth-muscle relaxant action of the drug. No accumulation of the drug following the multiple doses was recognized. AA-149 excreted in the 24-hour urines was about 3% of the dose, indicating that result well agrees with that of the single dose study.
The analysis of the serum concentration curves showed that administration of three times a day is recommendable for clinical use.抄録全体を表示PDF形式でダウンロード (881K) -
Safety and ToleranceMasatoshi TANAKA, Hiroaki HASUZAWA, Kazutoyo INANAGA, Nobuya OGAWA1977 年 8 巻 4 号 p. 501-514
発行日: 1977/12/30
公開日: 2010/06/28
ジャーナル フリーSafety and tolerance studies on a newly introduced antidepressant, Org GB 94 were performed on 6 healthy male volunteers ranging in age from 23 to 40 years old. Org GB 94 was administered orally in the dose range of 10-40 mg/day. After the drug administration, there were no unusual findings with the physical and hematological examinations, liver function tests, serum-electrolytes, urea nitrogen, pancreatic function tests, urinalysis, ECG and EEG, except for a tendency for a slight decrease in blood pressure and a slight tachycardia after medication
From these results, the safety and tolerance in the dose range of 10-40 mg Org GB 94/day were so confirmed that we feel we have obtained enough background data to proceed with the Phase II study.抄録全体を表示PDF形式でダウンロード (1779K) -
阿部 裕, 折田 義正, 上田 尚彦1977 年 8 巻 4 号 p. 515-519
発行日: 1977/12/30
公開日: 2010/06/28
ジャーナル フリーPDF形式でダウンロード (892K) -
関 隆1977 年 8 巻 4 号 p. 521-525
発行日: 1977/12/30
公開日: 2010/06/28
ジャーナル フリーPDF形式でダウンロード (915K)
- |<
- <
- 1
- >
- >|